Background
Methods
Data
Model construction
Value | Ref | |
---|---|---|
Incubation period | Gamma (μ=4.544, k=1/0.709) | [12] |
Transmission onset relative to the symptom onset | −4 + Gamma (μ=5.266, k=1/0.8709) | [12] |
Latent period | Incubation period + transmission onset relative to symptom onset | [12] |
Delays from symptom onset to diagnosis | Empirical distribution from the raw data | [12] |
Infectious period for asymptomatic cases | Gamma (μ=4, k=4/5) | [13] |
Proportion of asymptomatic cases | 52%, 50%, 45%, and 12% among individuals aged 0–4, 5–11, 12–17, and ≥18 years, respectively; or 50% in all age groups during the Omicron wave for sensitivity analysis | [14] |
Relative infectiousness of asymptomatic cases | 50% (25–75%) | |
Age groups (years) | [0–5], [5–10], [10–15], [15–20], [20–25], [25–30], [30–35], [35–40], [40–45], [45–50], [50–55], [55–60], [60–65], [65–70], [70–75], [≥75] | |
Vaccine effectiveness against the Delta variant infection | BNT162b2 one dose ≥21 days: 57% (95% CI 50–63%) | |
BNT162b2 two doses >14 days: 80% (95% CI 77–83%) | ||
ChAdOx1 one dose ≥ 21 days: 46% (95% CI 35–55%) | ||
ChAdOx1 two doses >14 days: 67% (95% CI 62–71%) | ||
mRNA-1273 one dose ≥21 days: 75% (95% CI 64–83%) | ||
mRNA-1273 two doses >14 days: 85% (95% CI 84–89%) | ||
Ad26.COV2.S >14 days: 69% (95% CI 67–71%) | ||
Vaccine effectiveness against the Omicron variant infection | BNT162b2 one dose ≥18 days: 42.8% (95% CI 40.3–45.1%) | [21] |
BNT162b2 one dose >42 days: 31.5% (95% CI 29.9–33.1%) | ||
BNT162b2 two doses <14 days: same value with one dose | ||
BNT162b2 two doses >21 days: 65.5% (95% CI 63.9–67.0%) | ||
BNT162b2 two doses >49 days: 48.7% (95% CI 47.1–50.2%) | ||
BNT162b2 two doses >84 days: 30.1% (95% CI 28.7–31.5%) | ||
BNT162b2 two doses >119 days: 15.4% (95% CI 14.2–16.6%) | ||
BNT162b2 two doses >154 days: 11.5% (95% CI 10.1–12.9%) | ||
BNT162b2 two doses >189 days: 8.8% (95% CI 7.0–10.5%) | ||
Interpolate linearly in between | ||
ChAdOx1 one dose ≥18 days: 17.7% (95% CI 14.3–21.0%) | ||
ChAdOx1 one dose >42 days: 16.7% (95% CI 12.3–20.0%) | ||
ChAdOx1 two doses <14 days: same value with one dose | ||
ChAdOx1 two doses >21 days: 48.9% (95% CI 39.2–57.1%) | ||
ChAdOx1 two doses >49 days: 33.7% (95% CI 25.0–41.5%) | ||
ChAdOx1 two doses >84 days: 28.6% (95% CI 20.9–35.6%) | ||
ChAdOx1 two doses >119 days: 17.8% (95% CI 13.4–21.9%) | ||
ChAdOx1 two doses >154 days: 4.0% (95% CI 1.9–6.1%) | ||
ChAdOx1 two doses >189 days: 0% | ||
Interpolate linearly in between | ||
mRNA-1273 one dose ≥18 days: 47.9% (95% CI 43.1–52.3%) | ||
mRNA-1273 one dose >42 days: 31.9% (95% CI 27.3–36.1%) | ||
mRNA-1273 two doses <14 days: same value with one dose | ||
mRNA-1273 two doses >21 days: 75.1% (95% CI 70.8–78.7%) | ||
mRNA-1273 two doses >49 days: 52.8% (95% CI 48.2–57.1%) | ||
mRNA-1273 two doses >84 days: 35.6% (95% CI 32.7–38.4%) | ||
mRNA-1273 two doses >119 days: 25.3% (95% CI 23.2–27.4%) | ||
mRNA-1273 two doses >154 days: 15.0% (95% CI 11.6–18.2%) | ||
mRNA-1273 two doses >189 days: 14.9% (95% CI 3.9–24.7%) | ||
Interpolate linearly in between | ||
Ad26.COV2.Sa | ||
Booster doseb >10 days: 67.3% (95% CI 65.9–68.6%) | ||
Booster doseb >21 days: 66.9% (95% CI 65.6–68.1%) | ||
Booster doseb >49 days: 55.0% (95% CI 54.2–55.8%) | ||
Booster doseb >84 days: 45.7% (95% CI 44.7–46.7%) | ||
Interpolate linearly in between |